Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart
  • Log out

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension

Gianluigi Savarese, Francesca Musella, Carmen D'Amore, Teresa Losco, Caterina Marciano, Paola Gargiulo, Giuseppe Rengo, Santo Dellegrottaglie, Eduardo Bossone, Dario Leosco, Pasquale Perrone-Filardi
European Respiratory Journal 2013 42: 414-424; DOI: 10.1183/09031936.00123712
Gianluigi Savarese
1Dept of Advanced Biomedical Sciences, Federico II University, Naples
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesca Musella
1Dept of Advanced Biomedical Sciences, Federico II University, Naples
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carmen D'Amore
1Dept of Advanced Biomedical Sciences, Federico II University, Naples
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teresa Losco
1Dept of Advanced Biomedical Sciences, Federico II University, Naples
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caterina Marciano
1Dept of Advanced Biomedical Sciences, Federico II University, Naples
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paola Gargiulo
1Dept of Advanced Biomedical Sciences, Federico II University, Naples
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giuseppe Rengo
1Dept of Advanced Biomedical Sciences, Federico II University, Naples
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Santo Dellegrottaglie
1Dept of Advanced Biomedical Sciences, Federico II University, Naples
2Cardiology, Villa dei Fiori Hospital, Acerra, Naples
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eduardo Bossone
3Cardiology, Cava de' Tirreni and Amalfi Coast Hospital, Salerno, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dario Leosco
1Dept of Advanced Biomedical Sciences, Federico II University, Naples
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pasquale Perrone-Filardi
1Dept of Advanced Biomedical Sciences, Federico II University, Naples
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: fpperron@unina.it
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The purpose of this study was to clarify whether changes in cardiopulmonary haemodynamics induced by pharmacological therapy correlate with exercise capacity and clinical events in patients with pulmonary arterial hypertension.

16 randomised trials including 2353 patients, followed up for 16.4±10.6 weeks, measuring cardiopulmonary haemodynamics by right heart catheterisation and reporting clinical events were included. Meta-analysis and meta-regression analysis were performed to assess the effects of treatments on clinical events and the relationship between haemodynamic changes (pulmonary artery pressure, pulmonary vascular resistance, cardiac index and right atrial pressure) and clinical events.

Treatments significantly reduced all-cause death (OR 0.5, 95% CI 0.3–0.7; p<0.01), hospitalisation for pulmonary arterial hypertension (OR 0.4, 95% CI 0.2–0.7; p<0.01), initiation of rescue therapy (OR 0.3, 95% CI 0.2–0.6; p<0.01) and the composite outcome (OR 0.3, 95% CI 0.3–0.5; p<0.01). No relationship was found between changes of haemodynamic parameters and clinical events, whereas changes of cardiac index and pulmonary vascular resistance significantly correlated with changes in the 6-min walking distance (r = 0.64, p = 0.03; r = -0.55, p = 0.04, respectively).

In patients with pulmonary arterial hypertension, improvements of cardiopulmonary haemodynamics observed in randomised clinical trials correlate with exercise capacity changes but do not predict clinical events in a short-term follow-up.

Introduction

Pulmonary arterial hypertension (PAH) is a chronic syndrome characterised by progressive deterioration of cardiopulmonary haemodynamics and right ventricular function, leading to impaired exercise capacity and premature death [1].

Right heart catheterisation (RHC) is recommended by guidelines to measure cardiopulmonary haemodynamic parameters with the purpose of diagnosing PAH, defining its aetiology, guiding therapeutic management and obtaining prognostic information [2, 3]. Yet, although the role of cardiopulmonary haemodynamic parameters is well recognised for the initial diagnostic workup, it is still uncertain whether changes of haemodynamics parameters reflect variations in the exercise capacity and in the incidence of subsequent clinical events in patients with PAH. In fact, although changes of cardiopulmonary haemodynamic parameters either represented the primary end-point [4–8] or were reported in several PAH randomised clinical trials [9–19], it has been not extensively investigated whether improvement of haemodynamic parameters correlates with improved exercise capacity. More importantly, the relationship of haemodynamic changes with major clinical events has never been assessed from randomised studies. However, this information is important for management of PAH patients to ultimately improve patient care.

Therefore, the aim of this meta-analysis was to investigate the relationship between changes of cardiopulmonary haemodynamic parameters induced by pharmacological therapies and exercise capacity, and clinical events in PAH patients enrolled in randomised clinical trials.

Materials and methods

Data sources and searches

The study was designed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement [20, 21]. The MEDLINE, Cochrane database, ISI Web of Science and SCOPUS database were searched for articles published in all languages until November 2011.

Study selection

Inclusion criteria were as follows. 1) Evaluation of cardiopulmonary haemodynamic by RHC at baseline and at end of follow-up; 2) report of clinical events (all-cause death, hospitalisation for PAH and/or lung or heart–lung transplantation, initiation of PAH rescue therapy); 3) comparison of active drug treatment versus placebo or of different doses of active drugs; and 4) randomised protocol design. Studies were identified using the major medical subject headings “pulmonary arterial hypertension”, “randomised” and “haemodynamics”. Hospitalisation was defined as end-point when it lasted at least 24 h and was determined by worsening of PAH clinical status. Rescue therapy was defined as interruption of blindness status of patients enrolled in clinical trials due to worsening clinical status.

Data extraction and quality assessment

Two reviewers independently screened articles according to fulfilment of inclusion criteria. Baseline characteristics, haemodynamic values (pulmonary artery pressure (PAP), pulmonary vascular resistance (PVR), right atrial pressure (Pra) and cardiac index) at baseline and end of follow-up, and clinical events were abstracted. A composite outcome including the above events was calculated and the assessment of the relationship between cardiopulmonary haemodynamic changes and composite outcome represented the first objective of the study. Additionally, the relationship between changes of haemodynamic parameters and changes of 6-min walking distance (6MWD) was also investigated. The quality of the trials was evaluated by Detsky’s method [22], whereas publication bias was assessed using Macaskill's modified test [23].

Of 14 906 articles identified by the initial search, 16 randomised trials including 2353 patients were included in the study (fig. 1). In 13 of these trials, including 1310 patients [4–8, 10, 12–17, 19], changes of 6MWD were also reported.

Figure 1–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1–

Meta-analysis flow chart.

Data synthesis and analysis

Weighted random-effects meta-regression analysis was performed with the metareg command [24] (STATA version 11.0, StataCorps, College Station, TX, USA) to test the relationship between cardiopulmonary haemodynamic changes from baseline to end of follow-up and clinical events, as previously reported [25]. For this analysis, the achieved differences between cardiopulmonary haemodynamic changes in active treatment and control groups were considered (ΔPAP, ΔPVR, ΔPra, and change in cardiac index (ΔCI)). For all meta-regression analyses, a random-effects model was used. Tau2 and the restricted maximum likelihood (REML) methods were employed to explain residual heterogeneity not explained by potential effect modifiers [26]. To further explore the influence of the degree of haemodynamic changes on the relationship with clinical events, for each haemodynamic parameter, studies were divided in tertiles with the first tertile including trials with the least favourable changes and the upper tertile including studies with the most favourable changes. Then, meta-regression was repeated, for each parameter, only for most favourable studies. Furthermore, the tertile (1, 2 or 3) to which each study belonged was tested as potential effect modifier in sensitivity analysis.

Unweighted Spearman correlation was used to test the relationship between changes in haemodynamics and changes in 6MWD.

Outcome meta-analysis

Odds ratios of the effect of treatments were calculated using the metan command (STATA, version 11.0; StataCorp, College Station, TX, USA) [27]. The choice to use odds ratio was driven by the retrospective design of the meta-analysis [27–29]. Overall estimates of effect were calculated with a fixed-effect model, random-effects model or Peto method as appropriate. Statistical homogeneity was assessed using Q and I2 statistics.

Sensitivity analysis

To assess the influence of potential effect modifiers on the association between haemodynamic changes and clinical events, meta-regression analyses were conducted, including the following variables as covariates, each separately: mean age, sex, race, type of PAH, baseline functional class, changes in 6MWD (Δ6MWD) from baseline to the end of follow-up, Detsky quality score, duration of follow-up, study publication year, baseline haemodynamic parameters and tertile of haemodynamic changes.

Results

Characteristics of included trials

Baseline characteristics of the 16 trials included in the study are reported in table 1. A total of 254 clinical events were reported in 2353 patients included in the meta-analysis. 385 patients were assigned to phosphodiesterase type 5 inhibitor inhibitors treatment, 942 to prostaglandin I2 analogues, 300 to endothelin receptor antagonists, 28 to imatinib, 107 to conventional therapy and 1047 to placebo. Conventional therapy was defined as any combination of therapy including diuretics, anticoagulants and oxygen supply, but not including specific PAH drugs. Mean follow-up duration was 16.4±10.6 weeks (range 8–52 weeks). The overall mean age of patients was 44.4±5.9 years and 76.5% were females.

View this table:
  • View inline
  • View popup
Table 1– Baseline characteristics of trials included in meta-analysis

Effects of therapies on pulmonary haemodynamic parameters and exercise capacity

Pooled weighted analysis of 16 trials reporting haemodynamic changes induced by active treatments showed a 12.7±6.4% increase of mean cardiac index, a 24.6±7.9% decrease of mean PVR, a 7.1±4.3% decrease of mean PAP and a 16.5±5.1% decrease of mean Pra. In 13 trials reporting exercise capacity, a 9.8±7.2% increase of mean 6MWD was observed.

A significant correlation was found between Δ6MWD and ΔCI (r = 0.6; p = 0.03) and between Δ6MWD and ΔPVR (r = -0.55; p = 0.04), but not between Δ6MWD and ΔPAP (r = 0.74; p = 0.09) and between Δ6MWD and ΔPra (r = -0.57; p = 0.19) (fig. 2).

Figure 2–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2–

Linear regression between change in 6-min walking distance (Δ6MWD) and a) change in pulmonary arterial pressure (ΔPAP), b) change in pulmonary vascular resistance (ΔPVR), c) change in cardiac index (ΔCI), and d) change in right atrial pressure (ΔPra).

Effects of therapies on outcomes

Pharmacological treatments led to significant reduction of the composite outcome without heterogeneity among studies (OR 0.3, 95% CI 0.3–0.5, comparison p<0.01, heterogeneity p = 0.11) (fig. 3). Additionally, each component of the composite outcome was significantly reduced by treatments, including all-cause death (OR 0.5, 95% CI 0.3–0.7, comparison p<0.01, heterogeneity p = 0.51) (online supplementary fig. S1), hospitalisation for PAH and/or lung or heart–lung transplantation (OR 0.4, 95% CI 0.2–0.7, comparison p<0.01, heterogeneity p = 0.82) (online supplementary fig. S2) and initiation of PAH rescue therapy (OR 0.3, 95% CI 0.2–0.6, comparison p<0.01, heterogeneity p = 0.23) (online supplementary fig. S3).

Figure 3–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3–

Odds ratio (OR) estimate of composite outcome in active treatment groups compared with control groups.

No relationship was found between ΔPAP, ΔPVR, ΔPra, ΔCI and the composite outcome by meta-regression analysis. Additionally, no relationship was found between ΔPAP, ΔPVR, ΔPra, ΔCI and each component of the composite outcome (tables 2 and 3) (fig. 4) (online supplementary figs S4–S6). Furthermore, lack of association between each haemodynamic parameter and clinical events was also confirmed for trials belonging to the tertile with the most favourable response.

View this table:
  • View inline
  • View popup
Table 2– Meta-regession analyses for the different outcomes measured
View this table:
  • View inline
  • View popup
Table 3– Haemodynamic values
Figure 4–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4–

Meta-regression between composite outcome and a) change in pulmonary arterial pressure (ΔPAP), b) change in pulmonary vascular resistance (ΔPVR), c) change in cardiac index (ΔCI), d) and change in right atrial pressure (ΔPra).

Sensitivity analysis

Results were confirmed when potential effect modifiers were introduced as covariates in the meta-regression analysis (online supplementary table S1).

Publication bias

No publication bias was detected by Macaskill's modified test for composite or single outcomes analysis.

Discussion

The main findings of the present analysis indicate that, in patients with PAH, changes of haemodynamic cardiopulmonary parameters observed during short-term randomised clinical trials investigating pharmacological therapies correlate with changes of exercise capacity evaluated by 6MWD but not with clinical events. In particular, a significant direct correlation was found between cardiac index increase and Δ6MWD, whereas a significant inverse correlation was found between PVR decrease and Δ6MWD. However, no variation of any cardiopulmonary haemodynamic parameter correlated to clinical events occurrence during the short-term follow-up of clinical trials.

Cardiopulmonary haemodynamic parameters in the management of PAH patients

It has been observed in large registry studies that increased PAP and Pra, as well reduced cardiac index, are associated with worse prognosis in patients with PAH [30–34]. From these observations, survival equations have been developed that represent a useful tool to predict prognosis in PAH patients. Survival equations developed from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) [31] and the French registry [33] include cardiopulmonary haemodynamic as well demographic and functional parameters, whereas in the Pulmonary Hypertension Correction equation, only cardiopulmonary haemodynamic parameters were significantly associated to prognosis [34]. Accordingly, several randomised trials in PAH have reported, as main [4–8] or secondary [9–19] end-points, changes of cardiopulmonary haemodynamic parameters induced by specific PAH therapies. However, the relationship between haemodynamic changes and either changes of exercise capacity or occurrence of clinical events is still unclear, leading the European Society of Cardiology and the European Respiratory Society to consider repeat of RHC after initiation of therapy or, in thr case of clinical deterioration as class II recommendation, with level of evidence C [2], whereas no clear indication for repeating invasive measurement of cardiopulmonary haemodynamic is made by the American College of Cardiology and American Heart Association guidelines on PAH [3].

Cardiopulmonary haemodynamic changes and exercise capacity in PAH

In the current study, a significant association was found by regression analysis between cardiopulmonary haemodynamic changes and exercise capacity, evaluated by the 6MWD test. In particular, the Δ6MWD directly correlated with cardiac index increase and inversely correlated with ΔPVR. Although both haemodynamic and exercise changes were concomitantly assessed in 13 randomised trials [4–8, 10, 12–17, 19], to our knowledge, only Barst et al. [10], in their pivotal epoprostenol study, investigated the correlation between haemodynamic and exercise parameters. In agreement with our meta-analysis, they also found a significant association between haemodynamic changes and improvement of 6MWD whereas, at variance with our study, they also reported in 81 patients analysed, a significant association between change in 6MWD and change in mean PAP and change in mean Pra. Thus, our aggregate results, in agreement with those of Barst et al [10] from a single clinical trial, indicate that haemodynamic improvement induced by vasodilator therapies in PAH plays a relevant role in the amelioration of exercise capacity.

Cardiopulmonary haemodynamic changes and short-term mortality/morbidity in PAH patients

The relationship between haemodynamic changes and clinical events has been investigated in nonrandomised studies [35–37] indicating that improvement of cardiac index and PAP [36] and decrease or no changes of PVR [35, 37] are associated with long-term clinical outcome in PAH patients. More recently, an analysis of patients undergoing subcutaneous treprostinil therapy followed up for 3 years, also reported that on-treatment changes of mixed oxygen venous saturation and of 6MWD predicted survival in PAH patients [38], whereas Nickel et al. [39] showed that changes of mixed oxygen venous saturation and cardiac index predicted survival over a 38-month follow-up in 109 patients with PAH.

The association between cardiopulmonary haemodynamic changes observed during randomised clinical studies and occurrence of clinical events using has never been systematically evaluated. The results of our meta-regression analysis indicate that no statistically significant association exists between pulmonary haemodynamic changes and clinical events occurring during the short-term follow-up of randomised studies. Explanation for the lack of correlation between haemodynamic improvement and events, and the reasons for the apparent discrepancy with observational nonrandomised studies, can only be hypothesised. It has been suggested that parameters reflecting right ventricular function are more predictive of clinical outcomes compared with cardiopulmonary haemodynamic changes. In a recent study, van de Veerdonk et al. [40] observed that right ventricular function, evaluated by magnetic resonance imaging, deteriorated in a subgroup of a population of 110 patients with treated PAH, despite reduction of PVR, and that in these patients, prognosis was poor irrespective of PVR changes. Thus, it is conceivable that improvement of haemodynamic parameters induced by therapies may occur despite deterioration or no changes in right ventricular function, thus correlating in the short-term with exercise capacity but not with clinical events [41, 42]. In fact, consistent with the current findings, in a recent meta-analysis exercise capacity changes reflected by 6MWD test in PAH did not correlate with clinical events [43].

Despite potential pathophysiological explanations, the lack of association between haemodynamic changes and events observed in our study must be interpreted with caution and not as evidence of uselessness of haemodynamic monitoring in PAH patients, for several considerations. First, our findings are restricted to randomised clinical trials and to the short period of observation, usually 3–4 months, commonly covered in these trials. This is quite a relevant aspect because, as outlined by Miller et al. [44], clinical trials usually include stable patients with potential survival bias, for whom a short-term period of observation may prevent the occurrence of a number of events statistically adequate to be tested for association with haemodynamic changes. In addition, randomised studies include different type of drugs and different degrees of haemodynamic changes, as well as different methods of evaluation of haemodynamic parameters. Thus, it cannot be excluded that an association may exist for responder patients and over a longer follow-up, as reported in nonrandomised studies or registries [45]. In addition, on treatment, haemodynamic changes are usually defined as the difference between baseline value and a snap-shot repeat evaluation under resting conditions and may, therefore, not be representative of the full haemodynamic benefit provided by therapies under daily life. In this regard, availability of implantable devices that provide a more comprehensive monitoring of haemodynamic changes may turn out to be valuable for risk stratification in PAH patients [46]. Thus, a definitive assessment of the cost-effectiveness of haemodynamic changes measurement in PAH patients cannot be made from the present analysis and deserve further exploration in prospective studies using different techniques [47].

Study limitations

Our study has some limitations. First, the analysis reported was based on aggregate rather than individual patient data. In addition, the current analysis does not allow us to exclude potential significant influence of the type of therapy on the association between haemodynamic effects and clinical events, and applies to the short follow-up of clinical trials. Thus, our findings cannot be generalised to long-term treatment of PAH. Furthermore, trials analysed included naive and already treated patients and, therefore, whether reported prognostic differences between naive and treated patients may have influenced our observations cannot be evaluated from our analysis [44]. Finally, since the technique used to measure cardiac index was not reported in several trials included in our meta-regression, an influence of the technique used, i.e. thermodilution or estimated or actual Fick method, on the association with clinical outcome cannot be excluded. Yet, there are also strengths of this analysis that are represented by the lack of publication bias and by the sensitivity analysis that confirmed that our findings were not influenced by several potential effect modifiers.

Conclusions

In the short duration of clinical trials, drug therapy favourably affects pulmonary haemodynamic parameters, exercise capacity and clinical outcome in PAH patients. Pulmonary haemodynamic changes, reported in randomised clinical trials, correlate with exercise capacity but not with clinical events, emphasising the need to keep on searching for markers of disease modification in PAH patients.

Footnotes

  • This article has supplementary material available from www.erj.ersjournals.com

  • Conflict of interest: None declared

  • Received August 7, 2012.
  • Accepted September 30, 2012.
  • ©ERS 2013

References

  1. ↵
    1. Simonneau G,
    2. Robbins IM,
    3. Beghetti M,
    4. et al
    . Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43–S54.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC), European Respiratory Society (ERS), International Society of Heart and Lung Transplantation (ISHLT), et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219–1263.
    OpenUrlFREE Full Text
  3. ↵
    1. McLaughlin VV,
    2. Archer SL,
    3. Badesch DB,
    4. et al
    . ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573–1619.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Galiè N,
    2. Rubin LJ,
    3. Hoeper M,
    4. et al
    . Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093–2100.
    OpenUrlCrossRefPubMedWeb of Science
    1. Humbert M,
    2. Barst RJ,
    3. Robbins IM,
    4. et al
    . Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353–359.
    OpenUrlAbstract/FREE Full Text
    1. McLaughlin VV,
    2. Oudiz RJ,
    3. Frost A,
    4. et al
    . Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 1257–1263.
    OpenUrlCrossRefPubMedWeb of Science
    1. Oudiz RJ,
    2. Schilz RJ,
    3. Barst RJ,
    4. et al
    . Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004; 126: 420–427.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Rubin LJ,
    2. Mendoza J,
    3. Hood M,
    4. et al
    . Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112: 485–491.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Badesch DB,
    2. Tapson VF,
    3. McGoon MD,
    4. et al
    . Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132: 425–434.
    OpenUrlPubMedWeb of Science
  7. ↵
    1. Barst RJ,
    2. Rubin LJ,
    3. Long WA,
    4. et al
    . A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296–302.
    OpenUrlCrossRefPubMedWeb of Science
    1. Barst RJ,
    2. McGoon M,
    3. McLaughlin V,
    4. et al
    . Beraprost therapy for pulmonary arterial hypertension. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119–2125.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Barst RJ,
    2. Langleben D,
    3. Frost A,
    4. et al
    . Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441–447.
    OpenUrlCrossRefPubMedWeb of Science
    1. Galiè N,
    2. Humbert M,
    3. Vachiéry JL,
    4. et al
    . Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496–1502.
    OpenUrlCrossRefPubMedWeb of Science
    1. Galiè N,
    2. Ghofrani HA,
    3. Torbicki A,
    4. et al
    . Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148–2157.
    OpenUrlCrossRefPubMedWeb of Science
    1. Ghofrani HA,
    2. Morrell NW,
    3. Hoeper MM,
    4. et al
    . Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 182: 1171–1177.
    OpenUrlCrossRefPubMedWeb of Science
    1. Jing ZC,
    2. Yu ZX,
    3. Shen JY,
    4. et al
    . Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2011; 183: 1723–1729.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Olschewski H,
    2. Simonneau G,
    3. Galiè N,
    4. et al
    . Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322–329.
    OpenUrlCrossRefPubMedWeb of Science
    1. Simonneau G,
    2. Barst RJ,
    3. Galie N,
    4. et al
    . Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800–804.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Simonneau G,
    2. Rubin LJ,
    3. Galiè N,
    4. et al
    . Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149: 521–530.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Moher D,
    2. Liberati,
    3. A,
    4. Tetzlaff J,
    5. et al
    . Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. Ann Intern Med 2009; 151: 264–269.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Costanzo P,
    2. Perrone-Filardi P,
    3. Petretta M,
    4. et al
    . Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients. J Hypertens 2009; 27: 1136–1151.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Detsky A,
    2. Naylor C,
    3. O'Rourke K,
    4. et al
    . Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol 1992; 45: 255–265.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Peters JL,
    2. Sutton AJ,
    3. Jones DR,
    4. et al
    . Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006; 295: 676–680.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Sharp SJ
    . Meta-analysis regression. Stata Tech Bull 1998; 42: 16–22.
    OpenUrl
  16. ↵
    1. Costanzo P,
    2. Savarese G,
    3. Rosano G,
    4. et al
    . Left ventricular hypertrophy reduction and clinical events. A meta-regression analysis of 14 studies in 12,809 hypertensive patients. Int J Cardiol 2012 [In press DOI: 10.1016/j.ijcard.2012.06.084].
  17. ↵
    1. Thompson SG,
    2. Sharp SJ
    . Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999; 18: 2693–2708.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Sharp S,
    2. Sterne J
    . Meta-analysis. Stata Tech Bull Reprints 1998; 7: 100–108.
    OpenUrl
    1. Whitehead A
    . Meta-Analysis of Controlled Clinical Trials. Chichester, John Wiley & Sons, 2002; p. 4.
  19. ↵
    1. Davies HT,
    2. Crombie IK,
    3. Tavakoli M
    . When can odds ratios mislead? Br Med J 1998; 316: 989–991.
    OpenUrlFREE Full Text
  20. ↵
    1. McLaughlin VVMD,
    2. McGoon MD
    . Pulmonary Arterial Hypertension. Circulation 2006; 114: 1417–1431.
    OpenUrlFREE Full Text
  21. ↵
    1. Benza RL,
    2. Miller DP,
    3. Gomberg-Maitland M,
    4. et al
    . Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164–172.
    OpenUrlAbstract/FREE Full Text
    1. D'Alonzo GE,
    2. Barst RJ,
    3. Ayres SM,
    4. et al
    . Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343–349.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Humbert M,
    2. Sitbon O,
    3. Chaouat A,
    4. et al
    . Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156–163.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Thenappan T,
    2. Shah SJ,
    3. Rich S,
    4. et al
    . Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010; 35: 1079–1087.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Sitbon O,
    2. Humbert M,
    3. Nunes H,
    4. et al
    . Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780–788.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. McLaughlin VV,
    2. Shillington A,
    3. Rich S
    . Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477–1482.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Provencher S,
    2. Sitbon O,
    3. Humbert M,
    4. et al
    . Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27: 589–595.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Benza RL,
    2. Gomberg-Maitland M,
    3. Naeije R,
    4. et al
    . Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. J Heart Lung Transplant 2011; 30: 982–989.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Nickel N,
    2. Golpon H,
    3. Greer M,
    4. et al
    . The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012; 39: 589–596.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. van de Veerdonk MC,
    2. Kind T,
    3. Marcus JT,
    4. et al
    . Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 2011; 58: 2511–2519.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Girgis RE
    . Predicting long-term survival in pulmonary arterial hypertension: more than just pulmonary vascular resistance. J Am Coll Cardiol 2011; 58: 2520–2521.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Dellegrottaglie S,
    2. Perrone-Filardi P,
    3. García-Alvarez A,
    4. et al
    . Serial phase-contrast MRI for prediction of pulmonary hemodynamic changes in patients with pulmonary arterial hypertension. Int J Cardiol 2012; 157: 140–142.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Savarese G,
    2. Paolillo S,
    3. Costanzo P,
    4. et al
    . Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? J Am Coll Cardiol 2012; 60: 1192–1201.
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Miller DP,
    2. Gomberg-Maitland M,
    3. Humbert M
    . Survivor bias and risk assessment. Eur Respir J 2012; 40: 530–532.
    OpenUrlFREE Full Text
  34. ↵
    1. Gomberg-Maitland M,
    2. Dufton C,
    3. Oudiz RJ,
    4. et al
    . Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective. J Am Coll Cardiol 2011; 57: 1053–1061.
    OpenUrlCrossRefPubMedWeb of Science
  35. ↵
    1. Frantz RP
    . Hemodynamic monitoring in pulmonary arterial hypertension. Expert Rev Respir Med 2011; 5: 173–178.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Farber HW,
    2. Foreman AJ,
    3. Miller DP,
    4. et al
    . REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. Congest Heart Fail 2011; 17: 56–64.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
View this article with LENS
Vol 42 Issue 2 Table of Contents
European Respiratory Journal: 42 (2)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension
Gianluigi Savarese, Francesca Musella, Carmen D'Amore, Teresa Losco, Caterina Marciano, Paola Gargiulo, Giuseppe Rengo, Santo Dellegrottaglie, Eduardo Bossone, Dario Leosco, Pasquale Perrone-Filardi
European Respiratory Journal Aug 2013, 42 (2) 414-424; DOI: 10.1183/09031936.00123712

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension
Gianluigi Savarese, Francesca Musella, Carmen D'Amore, Teresa Losco, Caterina Marciano, Paola Gargiulo, Giuseppe Rengo, Santo Dellegrottaglie, Eduardo Bossone, Dario Leosco, Pasquale Perrone-Filardi
European Respiratory Journal Aug 2013, 42 (2) 414-424; DOI: 10.1183/09031936.00123712
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Introduction
    • Materials and methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Lung structure and function
  • Pulmonary vascular disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Article

  • Lung volumes and survival in chronic lung allograft dysfunction
  • Umeclidinium in patients with COPD
  • EBUS-guided cryobiopsies in peripheral pulmonary lesions
Show more Original Article

Pulmonary Vascular Disease

  • COVID-19 and case fatality in pulmonary embolism
  • PULSAR: sotatercept for the treatment of PAH
  • Emerging phenotype of PAH patients carrying SOX17 variants
Show more Pulmonary Vascular Disease

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society